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The antibody response of inbred strains of mice to immunization with many 
synthetic branched  nmltichain polypeptides is  determined by an  autosomal, 
codominant gene, immune response-1  (Ir-1)  (1). 1 This gene locus lies within the 
routine major histocompatibility locus,  H-2  (2).  For  example,  H-2  b/b  strains 
respond  well  to  poly-L(Tyr,  Glu)-poly-D,L-Ala--poly-L-Lys [(T, G)-A--L]  and 
poorly  to  poly-L(His,  Glu)-poly-D,L-Ala--poly-L-Lys  [(H,G)-A--L];  H-2  ~l~ 
strains respond poorly to (T, G)-A--L and well to (H, G)-A--L,  and FI (H-2  k/b) 
hybrids respond  well  to both antigens. When the polypeptide  (T,G)-A--L is 
administered in complete Freund's adjuvant (CFA)  for the initial immuniza- 
tion,  both  H-2  bib  ("responder")  and  H-2  k/k  ("nonresponder")  strains  slowly 
develop  anti-(T,G)-A--L  antibodies  over  the  next  several  weeks,  with  the 
H-2  bib strain antibody levels slightly greater than those of the H-2  kt~ strain. A 
more striking difference occurs,  after a  second antigen  challenge with (T,G)- 
A--L in buffered saline, when antibody titers of H-2  b/b mice rise rapidly  while 
those of the H-2  ~/k mice remain constant or even decline slightly. If  the poly- 
peptide is first electrostatically complexed to a charged protein  carrier (such as 
methylated bovine serum albumin [MBSA]) and then used in the CFA regimen 
described above, both strains produce a  high  antibody response to the poly- 
peptide  after  a  secondary  challenge  with  the  insoluble  carrier-polypeptide 
complex in aqueous suspension. Analysis of the kinetics of antibody formation in 
this system may be  complicated by the effects of adjuvant on l}anphoid  (3) 
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110  THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  •  VOLUME 135, 1972 F.  CARL  GRUMET  111 
tissue, and by the possibility of persistent release of low doses of antigen from a 
CFA depot. In order to eliminate any effects of adjuvant, mice were immunized 
and  subsequently  boosted  with  (T, G)-A--L in  saline  only.  The resulting  anti- 
body  titers  were determined  as  a  function  of  time  after  antigen  challenge for 
primary, secondary,  and tertiary responses. The pattern of immune response to 
this  regimen  has  revealed  differences  between  responders  and  nonresponders 
that were not evident from previous studies. Although both responder and non- 
responder strains produced equally good IgM anti-(T, G)-A--L antibodies, only 
the responder  strains were able to produce  7S IgG antibody  to that antigen.  A 
model accounting for the observed results on the basis of  expression  of  the Ir-1 
gene in a  thymus-derived cell population is presented,  and subjected  to test in 
the accompanying paper. 
Materials and Methods 
Young adult mice of both sexes were obtained from the following sources:  C3H/HeJ from 
the Jackson Laboratory, Bar Harbor, Maine; C3H/HeTex from Texas Inbred Mice Company, 
Houston,  Texas; and C3H/HeJ and C3H/DiSn (origially obtained  from Dr. G.  D. Snell) 
from our own breeder colony at Stanford. C3H.SW mice, a strain congenic with the C3H/DiSn 
mice and differing only at the H-2 locus, were also obtained from our own colony. (C3H mice 
are H-2 klk and are (T,G)-A--L nonresponders, while C3H.SW mice are H-~  °tb and are (T,G)- 
A--L responders.) 
(T,G)-A--L 52  (tool  wt  180,000,  kindly provided  by  Dr.  Michael Sela,  Department  of 
Chemical Immunology, Weizmann Institute  of Science, Rehovot,  Israel)  was  prepared  in 
phosphate-buffered saline (PBS) to yield concentrations of from 0.001  to 100 gg/0.06 cc vol- 
ume, Mice were immunized and given booster doses of antigen intraperitoneally with 0.06 cc 
of the appropriate antigen concentration. In all cases,  the same dose of antigen was given as a 
secondary or tertiary stimulus as had been given in the initial immunization. Animals were bled 
from the retro-orbital sinus or the tail at the times indicated in the text. Equal aliquots of 
heparinized plasma from each animal within each experimental group were pooled and kept 
frozen until used for titration of antibody. 
Antibodies were assayed by a modification of techniques previously described (4).  (T,G)- 
A--L 52 and (T,G)-A-L 509 (tool wt 232,000, also provided by Dr. M. Sela) are completely cross- 
reacting antigens from different preparative batches  and  are interchangeable in this assay 
system (H.O. McDevitt and F. C. Grumet, unpublished observations). 50/Jl of antigen solu- 
tion containing 0.01  (or 0.005) gg (T,G)-A--L 509 labeled with 125I was incubated at 37°C for 
1 hr with 25/al of a 1 : 10 (or 1 : 25) dilution of an antisera pool. 50/11 of the appropriate dilution 
of a polyvalent rabbit-anti-mouse gamma globulin was then added and the mixture incubated 
for 2 hr at 37°C, and then centrifuged for 15 min at 10,000 g at 4°C. 50 IA of supernatant was 
counted in a  well-type gamma scintillation counter and  results were expressed  as per cent 
antigen bound in the precipitated complexes.  Sera from nonimmunized mice or mice given only 
PBS were used as controls to define a mean null antigen-bindlng level and gave zero 4-7.0% 
(4-2 sD) antigen binding. 
Disulfide bond  reduction of antisera with 2-mercaptoethanol  (2-Me)  was carried out  by 
incubating plasma pools with equal volumes of 0.1 ~ 2-Me for 30 min at 37°C, and then diluting 
the mixture with PBS for immediate titration as described above. 
Whole body X-irradiation was performed using a Philips X-ray machine (Philips Electronic 
Instruments, Mt. Vernon, N.Y.) calibrated at 15 ma and 250 kv to deliver 80 R/min for 10 
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Sera with 1-~aI-labeled  IgG or IgM myeloma markers were chromatographed on 0.6 X 21 cm 
columns of Sephadex G-200 (Pharmacia Fin  e Chemicals, Inc., Piscataway, N.J.)  equilibrated 
with 0.45 N PBS. Effluent aliquots were collected and tested for optical density at 280 m/~, and 
counted for radioactivity of the myeloma marker proteins. After concentration by the quanti- 
tative addition of dry Sephadex G-25 (fine), aliquots were titered for anti-(T,G)-A--L activity 
as previously described. 
RESULTS 
Primary Response.--Figs. 1 a and 1 b show the primary antibody response of 
C3H.SW  (responder  and  C3H  (nonresponder)  mice  given  graded  doses  of 
(T,G)-A--L in  PBS  on  day zero.  Except for  the  highest  antigen  dose,  both 
responder  and  nonresponder  mice demonstrated  similar  antibody production 
with an initial peak during  the 1st wk and persistent antibody levels over the 
next 3 wk. Responder mice receiving 100 #g of (T, G)-A--L developed a moder- 
ately delayed response that remained persistently elevated. In both strains the 
maximum early response occurred with the 1.0/~g dose. Lower antigen doses of 
0.01  and  0.001  /xg  (T,G)-A--L produced  responses  that  were  quantitatively 
lower but otherwise parallel go the 0.1 #g response. 
Secondary and Tertia~  3, Responses.--A group of C3H.SW and C3H mice were 
boosted at 7 and 30 days after their primary immunization, and bled serially for 
measurement of both total antigen binding and 2-Me-resistant (MeR) antigen- 
binding  capacity.  The  results  of  these  assays  are  presented  in  Figs.  2 a-2 d. 
Each figure shows the per cent of antigen bound  by untreated  and by 2-Me- 
treated plasma for both responder and nonresponder mice given the same doses 
of antigen. Both strains of mice produced antibody responses during the 1st wk 
after  immunization  that  were  composed  almost  entirely  of  2-Me-sensitive 
(MeS) antibody. After the first booster dose (secondary response), neither strain 
developed another MeS antibody peak and nonresponders also failed to develop 
any MeR anti-(T,G)-A--L  antibody.  In  contrast,  the  secondary  response  in 
C3H.SW  mice shows a rapid rise in MeR antibody that appears to be dose de- 
pendent up to a  plateau at 10 #g. After a  tertiary injection of antigen,  a  tran- 
sient fall in plasma antibody in all nonresponders was followed by a weak MeR 
antibody response that was inversely related to antigen dose (i.e., only the 0.1 
/~g  (T,G)-A--L-immunized mice  showed  a  significant  amount  of MeR  anti- 
body). Once again, there was no prominent MeS antibody peak in either strain. 
Responder  C3H.SW  mice showed a  slightly more vigorous dose-related  MeR 
antibody response to the tertiary stimulus than was  seen in their secondary re- 
sponses. Additional mice of each strain given 0.01  and 0.0~1/xg (T, G)-A--L on 
days zero,  7,  and 32  failed to show any  response to the secondary or tertiary 
antigen injection. 
In another experiment, Figs. 3 a-3 d, mice given a second injection of antigen 
on  day 30  developed secondary  responses  similar  to  those  after the  7th  day 
secondary responses previously described.  Low dose  immunization  (0.01  and 
0.001/ag) followed by a secondary stimulus at day 32 again failed to induce any A 
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FIGS. 1 a and 1 b.  Antibody response of (~) C3H.SW responder or (b)  C3H nonresponder 
mice to a single challenge at day zero of (T,G)-A--L over a dose range of 0.1-100 #g of antigen. 
Each point represents a plasma pool of five mice. 
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FIcs. 2 a and 2 b.  Total  (--)  and MeR  (  ..... ) antibody response of C3H.SW responder 
(-~>-)  and C3H  nonresponder  (-O-)  mice to  primary  (day zero),  secondary  (day  7),  and 
tertiary (day 30) challenge with (T,G)-A--L at {a) 0.1 ~g and (b) ].0,ug doses of antigen. Each 
point represents a plasma pool of five mice. 
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FIGS. 2 c and 2 d.  Total (  ,) and MeR (-----) antibody response of C3H.SW responder 
(-~-)  and  C3It  nonresponder  (-@-)  mice to primary  (day zero),  secondary  (day 7),  and 
tertiary (day 30) challenge with (T,G)-A-L at (c) 10 #g, and (d) 100 #g doses of antigen. Each 
point represents a plasma pool of five mice. Fig. 2 d reprinted by copyright permission from 
Ann. N.Y. Acad. Sci. 1971. 190. 
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FIGS. 3 a and 3 b.  Total (----)  and MeR  (  .....  )  antibody response of C3H.SW responder 
(-<~-)  and  C3H  nonresponder  (-O-)  mice  to  primary  (dab'  zero)  and  secondary  (day 30) 
challenge with (T,G)-A--L at (a) 0.1 #g and (b) 1.0 #g doses of antigen. Each point represents a 
plasma pool of five mice. 
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Fins. 3 c and 3 d.  Total (  ) and MeR (  .....  ) antibody response of C3H.SW responder 
(-~-)  and  C3H  nonresponder  (--e-)  mice to primary  (day  zero)  and  secondary  (day  30) 
challenge with (T,G)-A--L at (c) 10 gg and (d) 100 pg doses of antigen. Each point represents a 
plasma pool of five mice. 
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detectable  secondary response in  either  strain.  It should  be noted  that  only 
responder mice receiving 100 #g (T, G)-A--L developed MaR antibodies during 
the 2ndwk after immunization  before anyfurther injection of antigen was given. 
Characteristics of the MeS Antibody Response.-- 
Radiosensitivity of the MeS response:  Four C3H.SW and four C3H mice were 
mmunized intraperitoneally with  1.0 #g of (T,G)-A--L in PBS 4 hr after re- 
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FIG. 4 a.  Sephadex G-200 column chromatography of MeS anti-(T,G)-A--L antisera from 
C3H nonresponder mice bled 3 days after immunization. For each effluent aliquot, the optical 
density at 280 mtl (----) and the per cent antigen bound (-0-) were compared to the radio- 
activity (  ..... ) of an IgM 125I-labeled  myeloma marker. 
ceiving 800 R  whole body X-irradiation. None of these irradiated animals had 
detectable antibody to (T, G)-A--L when tested 6 days later. 
Column chromalography:  Fig. 4 demonstrates the results of column chroma- 
tography  of  anti-(T,G)-A--L  antisera  on  Sephadex  G-200.  The  anti- 
(T, G)-A--L antisera applied to the column consisted of a pool of plasma from 
four C3H mice immunized with 10 #g of (T, G)-A--L and bled 3 days later. This 
pool at a 1:25 dilution gave 25 % antigen binding for total antibody activity and 
3 %  antigen binding after 2-Me treatment.  Only the untreated  antiserum was F.  CARL  GRUMET  119 
applied  to the column. The  125I-labeled  myeloma markers  (kindly provided by 
Dr. Leonard Herzenberg,  Department  of Genetics,  Stanford University)  were 
GPC8, a ~G2a myeloma,  and  MOPC-104C,  a  "yM myeloma protein. From the 
figure it is clear that all of the antibody activity of this completely MeS anti- 
serum pool chromatographed with the IgM and not with the IgG marker. 
Antibody inhibition:  Anti-(T, G)-A--L antisera and normal mouse sera were 
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FIG. 4 b.  Sephadex G-200 column chromatography of MeS anti-(T,G)-A--L antisera from 
C3H nonresponder mice bled 3 days after immunization. For each effluent aliquot, the optical 
density at 280 m# (  .  ) and the per cent antigen bound (-O-) were compared to the radio- 
activity (  .....  ) of an IgG 12aI4abeled myeloma marker. 
incubated  with  equal  volumes  of  undiluted  goat-anti-mouse  IgM  antisera  2 
(also kindly provided by Dr. Leonard Herzenberg)  for 1 hr at 37°C and then 
overnight at 4°C. The mixture was then centrifuged for 15 rain at  10,000 g  at 
4°C, and the supernatant  removed for titration in the usual manner. Only the 
MeS antibody was inhibited by the anti-IgM antiserum as shown in Table I. 
The  MeS  antibodies  have  thus  been  shown  to belong  to  the  IgM  class  of 
2 This serum produced only a single 3'M line in immunelectrophnresis against normal mouse 
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immunoglobulins on the basis of column chromotography and reactivity with 
specific antisera. Antibodies that were MeR will  be considered to be primarily 
of the IgG class. The demonstration that the MeS antibody response is radiation 
sensitive is support for the belief that this is a true primary immune response. 
TABLE  I 
Anti-IgM Antiserum  Inhibition  of (T, G)-A--L  Binding  by MeR and MeS Anti-(T, G)-A--L 
A ntisera 
Anti-(T,  G)-A--L serum 
e//o Antigen binding  % Antigen binding 
after inhibition 
MeR  with anti-IgM  Total 
C3H.SW  1  0  0 
C3H  1  0  1 
C3H.SW  33  0  ,  4 
C3H  36  0  1 
C3H.SW  57  55  69 
DISCUSSION 
The kinetics of antibody formation in the immune response to (T,G)-A--L 
was studied by immunizing responder and nonresponder inbred strains of mice 
with antigen in aqueous solution. Four significant results were observed. First, 
both strains demonstrated equally good primary responses consisting of rapid 
formation of IgM antibody during the 1st wk after immunization. Except for 
the highest antigen dose in responder mice (which elicited IgG antibedy before 
a secondary stimulus), all animals maintained detectable IgM anti-(T, G)-A--L 
antibodies without IgG anti-(T,G)-A--L antibody formation for an additional 
3 wk. The duration of the IgM response is considerably longer than the half-life 
(0.5 days) for that class of immunoglobulin, implying continued production of 
IgM anti  (T,G)-A--L antibodies for a period of at least 1 month after immuni- 
zation (5). 
Second,  the most striking difference  between responder  and nonresponder 
mice was seen after secondary or tertiary antigen challenge: responders rapidly 
developed high titers of IgG antibody, while nonresponders  produced almost 
none. At the higher doses of antigen  (_  10 #g), this difference was qualitative, 
with nonresponders failing to mount even the feeble IgG response the>- showed 
after lower dose (_< 0.1 #g) tertiary antigen challenge. 
Third, not only were nonresponder mice incapable of producing appreciable 
IgG antibody, but they also failed to produce a significant increase in their IgM 
antibody after secondary or tertiary antigen challenge. 
Fourth, when challenged with high doses of antigen (100 ~g), responder mice 
developed IgG antibody without the need for further antigen challenge. 
Any hypothesis attempting to define the mechanism of action of the H-f- 
linked Ir-I  gene must account for these results. Three reasonable alternative t ~.  CARL  GRUMET  121 
mechanisms may be postulated. The first would localize the gene defect in non- 
responders to the marrow-derived precursors of antibody-producing cells, the so 
called B-cells  (6). The most significant evidence against this hypothesis is the 
ability of nonresponder mice immunized with (T, G)-A--L complexed to MBSA 
in CFA, to produce IgG anti-(T,G)-A--L antibody in titers equal to that of 
responder mice (immunized with (T,G)-A--L or with MBSA-(T,G)-A--L  in 
CFA)  (7).  Although  there  are  no  definitive studies  to  prove  that  MBSA- 
(T, G)-A--L-induced  antibodies  have  specificity  identical  to  that  of 
(T, G)-A--L-induced antibodies, data available from serial dilution titrations 
suggest similarity between these two antibody populations (8). Further evidence 
on this point comes from a parallel system in guinea pigs, where a histocompati- 
bility-linked gene controlling the ability to respond to poly-z-lysine (PLL) or to 
haptens on that molecule has been demonstrated (9). Complexing dinitrophenyl 
(DNP)-PLL to a  carrier protein, acetylated BSA (ABSA), induces high titer 
anti-DNP-PLL antibodies in the nonresponder strain 13 animal (10). Responder 
guinea pigs immunized with DNP-PLL and nonresponder guinea pigs immu- 
nized with DNP-PLL-ABSA produce high titers of anti-DNP-PLL antibodies 
that are of equal affinity as measured by fluorescence-quenching techniques. 
These results support  the concept that the nonresponder animals do not lack, 
in  their  antibody-producing cells,  the  ability to synthesize anti-(T,G)-A--L 
antibody, and that these cells are not the site of the Ir-1 gene effect. 
The second possible mechanism of gene action would focus attention on the 
early phase of the immune response, i.e., antigen recognition. In this hypothesis, 
nonresponder mice are unable to recognize (T, G)-A--L as foreign, or in some 
way are unable to present the antigen (or its "message") to the appropriate 
antibody-forming cells.  Because  F1  (responder  X  nonresponder)  and  tetra- 
parental (responder +  nonresponder) mice, who possess all the self-antigens of 
the nonresponder parent, are good responders it is unlikely that (T, G)-A--L is 
not recognized as an antigen because of any similarity to a nonresponder "self"- 
antigen (11).  Furthermore, both responder and nonresponder mice mount an 
equal  primary  IgM  response  to  the  antigen,  implying  that  IgM  anti- 
(T, G)-A--L-producing cells of both types recognize a similar degree of foreign- 
ness. Because both strains produce equal IgM primary responses, it is reasonable 
to assume that antigen processing and/or presentation to IgM antibody-forming 
cells is the same in each strain. If the Ir-1 gene effect is to be expressed during 
antigen presentation, then different or additional processing steps for antigen 
presentation to IgG antibody-forming cell precursors must be postulated. The 
gene defect in nonresponder strains could thus be an absence of an enzyme or cell 
surface component or cell population that is essential to the process of antigen 
recognition for cells destined to produce IgG antibodies. 
The third possible mechanism would localize  the Ir-1  gene defect slightly 
after antigen recognition in the immune response sequence. In this hypothesis, 
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cursor cells  would be the same for both responders and nonresponders. These 
cells  or their progeny could then begin  to make an IgM  response,  and in a 
responder strain could subsequently switch over to an IgG response. In non- 
responders, the absence of the enzyme or cell surface component or cell popula- 
tion necessary for inducing the shift (to IgG) in an antigen-stimulated, IgM- 
producing cell population would limit  that  animal  to an IgM  response only 
(except, of course, when  the  antibody-forming cell is  "tricked" by a  carrier 
protein such as MBSA into switching to IgG antibody formation). Evidence 
that specific cells may be initially committed to producing IgM antibodies, then 
enter a brief period of production of both IgM and IgG, and finally stabilize as 
IgG producers comes from several sources and will not be discussed here (12- 
15). Data available in the (T,G)-A--L system does not yet permit distinction 
between  separate  IgM  and IgG precursors as  opposed  to a  single precursor 
capable of switching from IgM to IgG. 
The conversion from IgM to IgG antibody production in responders given a 
single injection of 100/zg (T, G)-A--L must be considered in any comparison of 
responses of different classes of immunoglobulins. It is clear that an antigen dose 
threshold between 10 and 100/~g of (T, G)-A--L had to be exceeded before a 
single antigenic challenge would induce IgG antibody formation. The 100/~g 
primary antigen  dose  thus functioned effectively as a  combined primary and 
secondary immunization. If very early bleeding (less than 1 wk) and low dose 
(10/~g  or less)  antigen variables had  been  omitted,  the  100/~g  (T,G)-A--L 
response in  C3H.SW  could have been interpreted  as a  pure  IgG "primary" 
immune response. In itself, a pure IgG response would constitute strong evi- 
dence against a cellular IgM to IgG antibody shift. It is important, therefore, 
that any "pure" IgG immune responses be properly analyzed over a wide dose 
range during the earliest phases of the immune response to preclude the presence 
of a low-level early IgM response. 
One further interesting characteristic of the population of cells producing IgM 
antibodies is most  apparent  in  nonresponder mice,  where secondary antigen 
challenge fails to induce either an IgG  response  or  a  further  IgM  antibody 
response.  The absent  IgM  secondary response in  responders  might  at  least 
partly be attributable to the negative feedback exerted by the IgG antibodies 
produced in that strain (16). This mechanism probably is not effective, however, 
in the nonresponder strain which showed no IgG antibody production. It is also 
possible  that  the  initial  antigen  challenge  exhausted  or  paralyzed  the  IgM 
anti-(T,G)-A--L  antibody-producing  cells  in  the  nonresponder  mice.  Cell 
transfer  studies  currently in  progress  should  help in  excluding one of  these 
possibilities. 
Because only normal animals were utilized in this study, one must exercise 
great caution in analyzing results with reference to the current concept of the 
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marrow (B)  cells (6). Nevertheless,  the effect of thymectomy on the immune 
response to many antigens is a selective depression of IgG but not IgM antibody 
(17-22). This selective depression bears a  striking similarity to the pattern of 
anti-(T,G)-A--L antibody formation in  our nonresponders.  Thus,  responder 
mice show a  "normal" pattern of IgM  followed by IgG antibody formation, 
while nonresponders appear to be functionally thymectomized with respect to 
the specific antigen (T, G)-A--L. The results of a detailed study of the effects of 
thymectomy on the  antibody  response to  (T, G)-A--L  (presented in the sub- 
sequent report) support this concept (23). Although other mechanisms have not 
been excluded,  the data  presented  here, in conjunction with previous studies, 
are consistent with the hypothesis that the Ir-1 gene  effect is exerted  through 
thymus-derived cells which  influence  the  conversion of  (antibody-producing, 
bone marrow-derived) B-cells from IgM to IgG production. 
SUMMARY 
The kinetics  of antibody formation after  immunization with  the synthetic 
polypeptide poly-L(Tyr,Glu)-poly-D,L-Ala--poly-L-Lys  [(T,G)-A--L]  in  aque- 
ous solution were studied in genetically high  (H-2  b) and low (H-2  k) responder 
strains of mice. During the  1st wk after  immunization both strains developed 
brisk primary responses consisting of IgM antibody. With subsequent antigen 
challenge,  only the high responder mice showed immunological memory, pro- 
ducing high titers of IgG antibody. In contrast,  the low responder mice con- 
tinued to make a persistent low level of lgM antibody and appeared unreactive 
to secondary or tertiary antigen challenge. These data are consistent with the 
hypothesis  that  the  immune  response-1  gene  [controlling  response  to 
(T, G)-A--L] exerts its effect on the immune response at the time of switchover 
from IgM to IgG antibody production. 
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